KRTCAP2

Across TCGA pan-cancer cohorts, KRTCAP2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KRTCAP2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KRTCAP2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KRTCAP2 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where KRTCAP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTCAP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.394	<.001	9	view →
LUAD	Male	II,III,IV	+0.533	<.001	8	view →
LSCC	Male	All	+0.677	<.001	7	view →
PDAC	Female	All	−1.417	<.001	6	view →
COAD	All	III,IV	−0.159	.010	3	view →
OV	All	All	+0.699	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KRTCAP2–CCRCC

Open the CCRCC breakdown →